TARGET AUDIENCE

This conference is designed for dermatologists, dermatology fellows and residents, physician assistants, nurse practitioners, and other healthcare professionals who treat pigmentary disorders.

LEARNING OBJECTIVES

As a result of participating in this live activity, participants should be better able to: [LIST] [ITEM]Review the epidemiology, prevalence and etiopathogenesis of pigmentary disorders across all skin phototypes. [ITEM]Identify the clinical features of pigmentary disorders that contribute to the burden of disease, psychosocial implications, and diminished quality of life. [ITEM]Apply best practices for achieving a timely and accurate diagnosis of pigmentary disorders to initiate appropriate treatment. [ITEM]Evaluate available clinical evidence on the mechanism of action, efficacy, safety, and tolerability of available treatment modalities for pigmentary disorders. [ITEM]Discuss new and emerging treatments in the context of disease pathogenesis, as well as recent clinical trial results. [ITEM]Summarize features and benefits of cosmeceutical and photoprotection product use as part of a comprehensive treatment care regimen for dyspigmentation. [ITEM]Select multimodality treatment plans for pigmentary disorders that reflect current evidence-based recommendations and take patient-specific factors into consideration. [ITEM]Describe the indications for the use of lasers and phototherapy devices in patients with pigmentary disorders across skin phototypes, and how to mitigate the risks of complications with laser use. [ITEM]Integrate mental health screening and patient education strategies to encourage adherence to therapeutic regimens, prevent recurrence, and improve quality of life. [/LIST]
 

JOINT ACCREDITATION STATEMENT


 

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Global Academy for Medical Education. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

[bold]Physician Continuing Medical Education[/bold] The Postgraduate Institute for Medicine designates live activity for a maximum of 11.50 [bold][italic]AMA PRA Category 1 Credits™.[/italic][/bold] Physicians should claim only the credit commensurate with the extent of their participation in the activity. [bold]Continuing Nursing Education[/bold] The maximum number of hours awarded for this Continuing Nursing Education activity is 11.50 contact hours. Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined.

Continuing Physician Assistant Education 

Postgraduate Institute for Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 11.50 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation. 

Credit amount subject to change  
 

DISCLOSURES OF CONFLICTS OF INTEREST

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  The existence or absence of COI for everyone in a position to control educational content will be disclosed to participants prior to the start of each activity.